Your browser doesn't support javascript.
loading
[Drug-induced cognitive impairment and dementia]. / Lekarstvenno-indutsirovannye kognitivnye narusheniya i dementsiya.
Ostroumova, O D; Ostroumova, T M; Kochetkov, A I; Vorobyova, A E; Gadzhibekov, A A; Sychev, D A.
Afiliação
  • Ostroumova OD; Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
  • Ostroumova TM; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Kochetkov AI; Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
  • Vorobyova AE; Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
  • Gadzhibekov AA; Central Clinical Hospital «RZD-Medicine¼, Moscow, Russia.
  • Sychev DA; Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova ; 124(4. Vyp. 2): 77-85, 2024.
Article em Ru | MEDLINE | ID: mdl-38696155
ABSTRACT
One of the reasons for the development or worsening of cognitive impairment (CI) may be the use of a number of drugs non-steroidal anti-inflammatory drugs, antiarrhythmics, antidepressants, glucocorticosteroids, antitumor drugs and a number of others. The negative effect of drugs on cognitive functions is realized due to many pathophysiological mechanisms disruption of hormonal regulation, decreased neuronal excitability, increased activity of gamma-aminobutyric acid receptors, decreased cerebral circulation, atrophic changes in the brain; many mechanisms have not been fully established. Risk factors for the development of drug-induced CIs are old age or childhood, brain damage, chronic diseases, genetic factors, the patient's initial CI, polypharmacy, dose and duration of drug use, acute infectious diseases, metabolic disorders, dehydration, acute urinary retention, etc. To diagnose and differentially diagnose drug-induced CI, it is necessary to establish a connection between the start of taking a suspected drug-inducer and a decrease in cognitive functions. The first step in the treatment of drug-induced CI is the abolition of an inducer drug or a reduction in its dose, in cases where it is impossible to discontinue the drug and there is no replacement, special slow-release dosage forms can be considered. The main measures to prevent drug-induced CI include the use of drugs with the lowest risk of their development, assessment of drug interactions, and the use of modern scales to assess the risk of developing this side-effect (anticholinergic burden scale, etc.).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Disfunção Cognitiva Idioma: Ru Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Disfunção Cognitiva Idioma: Ru Ano de publicação: 2024 Tipo de documento: Article